[go: up one dir, main page]

BRPI0817223B8 - inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação - Google Patents

inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação

Info

Publication number
BRPI0817223B8
BRPI0817223B8 BRPI0817223A BRPI0817223A BRPI0817223B8 BR PI0817223 B8 BRPI0817223 B8 BR PI0817223B8 BR PI0817223 A BRPI0817223 A BR PI0817223A BR PI0817223 A BRPI0817223 A BR PI0817223A BR PI0817223 B8 BRPI0817223 B8 BR PI0817223B8
Authority
BR
Brazil
Prior art keywords
mdm2
interaction
inhibitors
combination
pharmaceutical composition
Prior art date
Application number
BRPI0817223A
Other languages
English (en)
Inventor
Schoentjes Bruno
Storck Pierre-Henri
Coupa Sophie
Sophie Poncelet Virginie
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38910911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0817223(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0817223A2 publication Critical patent/BRPI0817223A2/pt
Publication of BRPI0817223B1 publication Critical patent/BRPI0817223B1/pt
Publication of BRPI0817223B8 publication Critical patent/BRPI0817223B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

inibidores da interação entre mdm2 e p53. a presente invenção refere-se a compostos de fórmula (i), a seu uso como inibidor de uma interação de p53-mdm2 bem como composições farmacêuticas compreendendo os referidos compostos: em que n, m, p, s, t r1, r2, r3, r4, r5, r6, r7, r20, x, y, q e z têm significados definidos.
BRPI0817223A 2007-09-21 2008-09-18 inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação BRPI0817223B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07116889 2007-09-21
PCT/EP2008/062433 WO2009037308A1 (en) 2007-09-21 2008-09-18 Inhibitors of the interaction between mdm2 and p53

Publications (3)

Publication Number Publication Date
BRPI0817223A2 BRPI0817223A2 (pt) 2015-03-10
BRPI0817223B1 BRPI0817223B1 (pt) 2020-04-07
BRPI0817223B8 true BRPI0817223B8 (pt) 2021-05-25

Family

ID=38910911

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817223A BRPI0817223B8 (pt) 2007-09-21 2008-09-18 inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação

Country Status (23)

Country Link
US (4) US9573933B2 (pt)
EP (1) EP2203440B1 (pt)
JP (1) JP5438007B2 (pt)
CN (2) CN101868453A (pt)
AR (1) AR068627A1 (pt)
AT (1) ATE502934T1 (pt)
AU (1) AU2008300527B2 (pt)
BR (1) BRPI0817223B8 (pt)
CA (1) CA2699849C (pt)
CL (1) CL2008002798A1 (pt)
DE (1) DE602008005784D1 (pt)
DK (1) DK2203440T3 (pt)
ES (1) ES2363838T3 (pt)
HR (1) HRP20110394T1 (pt)
JO (1) JO2704B1 (pt)
MX (1) MX2010003060A (pt)
PA (1) PA8796901A1 (pt)
PE (1) PE20090817A1 (pt)
RU (1) RU2477724C2 (pt)
SI (1) SI2203440T1 (pt)
TW (1) TWI434841B (pt)
UY (1) UY31349A1 (pt)
WO (1) WO2009037308A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
MY152018A (en) 2009-02-04 2014-08-15 Janssen Pharmaceutica Nv Indole derivatives as anticancer agents
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
CN102321034B (zh) * 2011-06-07 2014-08-13 中国人民解放军第二军医大学 硫代苯二氮卓类化合物及其作为药物的用途
CA2853729A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
ES2410704B1 (es) * 2011-11-28 2014-04-29 Universitat De Barcelona Indoleninas fluoradas útiles para el tratamiento del cáncer.
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CN115137529B (zh) 2016-12-21 2025-12-02 特里弗洛心血管公司 心脏瓣膜支撑装置及用于制造和使用该装置的方法
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1734401A (en) * 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
ES2566056T3 (es) * 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
AU2002357728A1 (en) * 2001-11-09 2003-05-19 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
US7540139B2 (en) * 2004-08-16 2009-06-02 Rowse Hydraulic Rakes Co., Inc. Foldable hay rake
JP5156378B2 (ja) * 2004-09-22 2013-03-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
WO2006089286A2 (en) * 2005-02-18 2006-08-24 Acadia Pharmaceuticals Inc. Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor compounds useful for the treatment and prevention of pain and screening methods therefor
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US8232298B2 (en) 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
PA8792401A1 (es) * 2007-08-06 2009-03-31 Janssen Pharmaceutica Nv Fenilendiaminas
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53

Also Published As

Publication number Publication date
PE20090817A1 (es) 2009-07-02
DK2203440T3 (da) 2011-06-20
US11583524B2 (en) 2023-02-21
BRPI0817223A2 (pt) 2015-03-10
AU2008300527A1 (en) 2009-03-26
EP2203440A1 (en) 2010-07-07
HRP20110394T1 (hr) 2011-06-30
AR068627A1 (es) 2009-11-25
TWI434841B (zh) 2014-04-21
MX2010003060A (es) 2010-04-07
CN104761541A (zh) 2015-07-08
ATE502934T1 (de) 2011-04-15
RU2010115765A (ru) 2011-10-27
US20170112818A1 (en) 2017-04-27
CL2008002798A1 (es) 2009-06-05
JP5438007B2 (ja) 2014-03-12
ES2363838T3 (es) 2011-08-17
AU2008300527B2 (en) 2013-08-29
BRPI0817223B1 (pt) 2020-04-07
CN101868453A (zh) 2010-10-20
TW200930709A (en) 2009-07-16
CA2699849A1 (en) 2009-03-26
SI2203440T1 (sl) 2011-07-29
EP2203440B1 (en) 2011-03-23
UY31349A1 (es) 2009-03-31
RU2477724C2 (ru) 2013-03-20
JP2010539220A (ja) 2010-12-16
US20200121667A1 (en) 2020-04-23
US20100240637A1 (en) 2010-09-23
PA8796901A1 (es) 2009-05-15
CA2699849C (en) 2015-10-27
DE602008005784D1 (de) 2011-05-05
US9573933B2 (en) 2017-02-21
JO2704B1 (en) 2013-03-03
WO2009037308A1 (en) 2009-03-26
US20180263966A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
BRPI0817223B8 (pt) inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação
BRPI0515594A (pt) inibidores da interação entre mdm2 e p53
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
BR112014000713A2 (pt) derivados de indol substituído como moduladores de gama secretase
ATE547415T1 (de) Inhibitoren der wechselwirkung zwischen mdm2 und p53
DOP2010000178A (es) Peptidil nitrilos como inhibidores de dipeptidil peptidasa i
BRPI0617167B8 (pt) sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
BRPI1008473A2 (pt) compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
ECSP066375A (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
ATE470665T1 (de) Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
BRPI0911208A2 (pt) moduladores inflamatórios antioxidantes: ácido oleanólico derivados com saturação no c-anel.
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
BRPI0717970C1 (pt) composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
SV2011003855A (es) Heteroarilos sustituidos
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
PA8855001A1 (es) Monocarbamas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2792 DE 09-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.